Cabazitaxel
Description
Cabazitaxel is an anticancer agent, used along with prednisone for the treatment of prostate cancer. It should be used under the supervision of a qualified physician. Close monitoring of blood cell count is necessary while receiving this medication. This medicine is not recommended for use in patients below 18 years of age.
QUICK LINKS:
Side effects
Major & minor side effects for Cabazitaxel
- Decrease in blood cell count
- Diarrhea
- Nausea and vomiting
- Loss of appetite
- Infections
- Difficulty in breathing
- Cough
- Hair loss
- Blood in urine
- Back pain
- Fever and chills
- Unusual tiredness and weakness
Uses of Cabazitaxel
What is it prescribed for?
- Prostate cancer
Read More
Concerns
Commonly asked questions
- Onset of actionThe peak effect of this medicine can be observed within 1 hour of administration of dose.
- Duration of effectThe amount of time for which this medicine remains active in the body is not clinically established.
- Safe with alcohol?Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
- Is it habit forming?No habit-forming tendencies were reported.
- Usage in pregnancy?This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
- Usage while breast-feeding?This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
Allergy
This medicine is not recommended for use in patients with a known allergy to Cabazitaxel or any other inactive ingredients present along with it.
Neutrophils count
This medicine is not recommended for use in patients with neutrophils count equal to or less than 1,500 cells/mm3 due to the increased risk of worsening of the patient's condition.
Severe liver impairment
This medicine is not recommended for use in patients with severe liver impairment due to the increased risk of worsening of the patient's condition.
Warnings for special population
Pregnancy
This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine.
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period of time or prescribe an alternative medicine based on your clinical condition.
General warnings
Bonemarrow suppression
This medicine may cause bone marrow suppression which in turn lowers the white blood cell count (neutrophils) and platelets. Close monitoring of blood cell count is necessary. The baseline of the blood cell count should be obtained before initiation of the treatment. Do not start the treatment if the neutrophils count is less than 1500 cells/mm3.
Liver injury
This medicine is not recommended for use in patients with severe liver injury and caution is advised in mild to moderate condition with appropriate dose adjustments. The baseline of the liver function tests should be obtained before starting the treatment. Regular monitoring of the liver function is recommended while receiving this medicine.
Gastrointestinal Disorders
This medicine may cause severe gastrointestinal complications like nausea, vomiting, severe diarrhea, gastrointestinal bleeding and perforations, colitis, etc. Close monitoring of symptoms is necessary and treatment should be initiated accordingly. Your doctor may consider dosage adjustments, treatment delay or discontinuation based on the clinical condition.
Lung toxicity
This medicine may increase the risk of toxic effects on the lungs and could lead to respiratory failure. The lung toxicity is dose-related and close monitoring of lung function is recommended during the therapy with this medicine. Any symptoms of lung toxicity should be informed to the doctor on priority. The treatment should be discontinued if such symptoms appear.
Severe allergic reactions
Use of this medicine may cause some serious skin reactions. Your doctor may prescribe you the premedication regimen which includes antihistamine, corticosteroid, and H2 antagonist before each dose of Cabazitaxel to prevent such interactions. Discontinue the treatment if any symptoms of allergy appear and do not restart.
Kidney Failure
This medicine should be used with caution since it may increase the risk of kidney failure. Regular monitoring of the kidney function tests is necessary while receiving this medicine. Report any unusual symptoms to the doctor on priority. An alternative treatment option should be considered in some cases based on the clinical condition.
Use in elderly
This medicine should be used with caution in elderly patients since the risk of adverse effects is significantly high.
Use in Children
This medicine is not recommended for use in patients below 18 years of age since the safety and efficacy of use are not clinically established.
Missed Dose
Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. If you miss any chemotherapy session you should contact your doctor immediately and fix an appointment as recommended.
Overdose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol
Description
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Instructions
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Live attenuated vaccines and related products
Etanercept
Adalimumab
Clozapine
Atorvastatin
Disease interactions
Infections
This medicine should be used with caution in patients suffering from infections due to the increased risk of bone marrow suppression which causes worsening of infections. Report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended. An alternative treatment option should be considered in some cases based on the clinical condition.
Bone marrow suppression
This medicine should be used with extreme caution in patients suffering from bone marrow suppression which causes anemia and infections due to the increased risk of worsening of the patient's condition. Report any signs or symptoms suggesting infection such as bleeding or symptoms of anemia, fever, sore throat, or local infection to your doctor during the therapy with this medicine. Close clinical monitoring of hematopoietic function is recommended. An alternative treatment option should be considered in some cases based on the clinical condition.
Liver Disease
This medicine should be used with caution in patients with mild to moderate liver diseases due to the increased risk of adverse effects. Regular monitoring of the liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Kidney Disease
This medicine should be used with caution in patients with kidney diseases due to the increased risk of adverse effects. Regular monitoring of the kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Gastrointestinal Disorders
This medicine should be used with caution in patients with gastrointestinal complications due to the increased risk of worsening of the patient's condition. Report any unusual symptoms to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Lung dysfunction
This medicine should be administered with caution in patients with preexisting pulmonary dysfunction due to the increased risk of interstitial lung disease and acute respiratory distress syndrome. Report any unusual symptoms to the doctor on priority. Close monitoring of lung function tests is recommended while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine. The blood cells count and liver function should be assessed before starting the treatment. Any signs and symptoms of gastrointestinal tract disorders, liver and lung dysfunction should be reported to the doctor on priority.
Miscelleneous
How it works
It works by stopping the growth of cells by acting on microtubules that provide structure and motor function of the cells.
Legal Status
Classification
Category
Antineoplastics, Mitotic inhibitors
Schedule
Schedule H
[Internet]. Dailymed.nlm.nih.gov. 2018 [cited 6 December 2018]. Available from:
[Internet]. Medicines.org.uk. 2018 [cited 6 December 2018]. Available from:
Cabazitaxel - DrugBank [Internet]. Drugbank.ca. 2018 [cited 6 December 2018]. Available from:
[Internet]. Ebs.tga.gov.au. 2018 [cited 6 December 2018]. Available from:
JEVTANA® (cabazitaxel) injection for Advanced Prostate Cancer [Internet]. Jevtana.com. 2018 [cited 6 December 2018]. Available from:
Information on this page was last updated on 28 Jan 2019
Disclaimer
We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.